858523-37-2

Basic information

• Product Name: (4-Bromo-2-methoxyphenyl)acetonitrile
• Synonyms: (4-Bromo-2-methoxyphenyl)acetonitrile;4-BroMo-2-Methoxybenzyl cyanide;4-Bromo-2-methoxybenzeneacetonitrile
• CAS NO: 858523-37-2
• Molecular Formula: C₉H₈BrNO
• Molecular Weight: 226.06992
• Mol File: 858523-37-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 308.408ºC at 760 mmHg
• Flash Point: 140.32ºC
• Appearance: /
• Density: 1.451g/cm3
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.556
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (4-Bromo-2-methoxyphenyl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Bromo-2-methoxyphenyl)acetonitrile(858523-37-2)
• EPA Substance Registry System: (4-Bromo-2-methoxyphenyl)acetonitrile(858523-37-2)

Safety Data

• Hazardous Substances Data: 858523-37-2(Hazardous Substances Data)

Usage

General Description

(4-Bromo-2-methoxyphenyl)acetonitrile is a chemical compound with the molecular formula C9H8BrNO. It is a pale yellow solid with a molecular weight of 220.07 g/mol. (4-Bromo-2-methoxyphenyl)acetonitrile is used in the field of organic synthesis as a reagent for the preparation of various pharmaceuticals and other organic compounds. It is known for its potential use as an intermediate in the synthesis of biologically active molecules and pharmaceutical agents. The presence of a bromine atom in the compound's structure makes it a valuable building block for the synthesis of diverse chemical compounds. Overall, (4-Bromo-2-methoxyphenyl)acetonitrile plays an important role in the production of various pharmaceuticals and organic compounds due to its unique chemical properties and reactivity.

InChI:InChI=1/C9H8BrNO/c1-12-9-6-8(10)3-2-7(9)4-5-11/h2-3,6H,4H2,1H3

Upstream product

• 854778-42-0 4-bromo-1-(bromomethyl)-2-methoxybenzene 
• 67868-73-9 5-bromo-2-methylphenol methyl ether 
• 36138-76-8 5-bromo-2-methylphenol 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 43192-33-2 4-bromo-2-methoxybenzaldehyde 

Downstream Products

• 1026089-09-7 2-(4-bromo-2-methoxyphenyl)acetic acid 
• 1366131-97-6 3-[4-bromo-2-(methyloxy)phenyl]-4-fluoro-6-iodo-2-quinolinamine 
• 1366130-08-6 N-[5-{2-amino-3-[4-bromo-2-(methyloxy)phenyl]-4-cyano-6-quinolinyl}-2-(methyloxy)-3-pyridinyl]-2,4-difluorobenzenesulfonamide 
• 1366131-98-7 2-amino-3-[4-bromo-2-(methyloxy)phenyl]-6-iodo-4-quinolinecarbonitrile 
• 1122568-20-0 2-(4-bromo-2-methoxyphenyl)-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}propanenitrile 

Relevant articles and documents

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leuke

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure (a) including pharmaceutically acceptable salts, esters, solvates, stereoisomers, and prodrugs thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist and a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.